Partnering

Orlance partners with other companies to develop new vaccines, immunotherapies, and delivery platforms for a wide variety of diseases.

If you're a potential Partner.

Series A, corporate, foundation or government funding and collaboration, MACH-1 initial clinical programs for lead influenza and Covid-19 vaccine assets

DNA and mRNA clinical vaccine candidates in need of optimized formulation and delivery

Kris Aalto

206-792-5069
kaalto@orlance.com
info@orlance.com